Premium
The melanocortin receptor agonist NDP‐MSH impairs the allostimulatory function of dendritic cells
Author(s) -
Rennalls La’Verne P.,
Seidl Thomas,
Larkin James M. G.,
Wellbrock Claudia,
Gore Martin E.,
Eisen Tim,
Bruno Ludovica
Publication year - 2010
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1111/j.1365-2567.2009.03210.x
Subject(s) - agonist , melanocortin , melanocortin 4 receptor , melanocortin receptor , endocrinology , function (biology) , receptor , melanocortin 3 receptor , medicine , melanocortin 1 receptor , biology , microbiology and biotechnology , chemistry , genetics , gene , allele
Summary As α‐melanocyte‐stimulating hormone (α‐MSH) is released by immunocompetent cells and has potent immunosuppressive properties, it was determined whether human dendritic cells (DCs) express the receptor for this hormone. Reverse transcription–polymerase chain reaction detected messenger RNA specific for all of the known melanocortin receptors in DCs. Mixed lymphocyte reactions also revealed that treatment with [Nle 4 , DPhe 7 ]‐α‐MSH (NDP‐MSH), a potent α‐MSH analogue, significantly reduced the ability of DCs to stimulate allogeneic T cells. The expression of various cell surface adhesion, maturation and costimulatory molecules on DCs was also investigated. Although treatment with NDP‐MSH did not alter the expression of CD83 and major histocompatibility complex class Ι and ΙΙ, the surface expression of CD86 (B7.2), intercellular adhesion molecule (ICAM‐1/CD54) and CD1a was reduced. In summary, our data indicate that NDP‐MSH inhibits the functional activity of DCs, possibly by down‐regulating antigen‐presenting and adhesion molecules and that these events may be mediated via the extracellular signal‐regulated kinase 1 and 2 pathway.